However, users may print, download, or email articles for individual use. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. Copyright of Clinical & Applied Thrombosis/Hemostasis is the property of Sage Publications Inc.However, a higher prevalence of ICH bleeds was noted in the andexanet alfa group. Conclusions: Anticoagulant reversal therapy with idarucizumab was associated with significantly lower adjusted mean total hospital and ICU costs compared with andexanet alfa. ![]() Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8% p = 0.001). Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during –, and received idarucizumab or andexanet alfa.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |